Q-omics provides the consensus-scored MYO18B profile across patient tissues and cancer cell-line models. MYO18B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MYO18B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MYO18B RNA expression shows 13,672 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where MYO18B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO18B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO18B survival associations across molecular data types. MYO18B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO18B RNA expression–survival associations across cancer types. High MYO18B expression shows unfavorable associations in KIRP, KICH, THCA and LIHC, but favorable associations in LGG and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MYO18B RNA expression.
This table summarizes MYO18B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO18B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO18B shows lower tumor expression in BLCA, KIRP, KIRC and KICH and higher tumor expression in COAD and LIHC. The COAD box plot shows higher MYO18B RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p = .004).
This table shows molecular features associated with MYO18B in patient tissues and cancer cell lines. In patient samples, MYO18B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO18B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
